[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"JW Pharmaceutical\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":157},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,67,91,114,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100622013","phase-3-to-evaluate-the-efficacy-and-safety-of-klh-2109-in-patients-with-uterine-fibroids-and-menorrhagia-100622013",false,"NCT07378098","to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia","A Multi-center, Randomized, Double-blind, Active-controlled, Parallel, Phase 3 Study to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia","Inclusion Criteria:\n\n* Individuals diagnosed with uterine fibroids\n\nExclusion Criteria:\n\n* Metrorrhagia or anovulatory bleeding\n* Patients with a history of total hysterectomy or bilateral oophorectomy","FEMALE","19 Years",{"count":19,"type":20},254,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The goal of this clinical trial was to determine whether the investigational drug KLH-2109 is effective for treating excessive menstrual bleeding in patients with uterine fibroids. Uterine fibroids are benign tumors that grown in the uterus.\n\nThe primary objectives of this trial were to answer the following questions:\n\n* Does KLH-2109 lower the amount of menstrual bleeding?\n* Does KLH-2109 reduce menstrual bleeding?\n* Is KLH-2109 safe for participants to use?\n\nInvestigators will compare KLH-2109 with a standard of care treatment (control) to determine which treatment is more effective.\n\nParticipants will be required to follow:\n\n* Take either KLH-2109 or the common treatment as a pill\n* Visit the clinic regularly for health checkups and safety tests\n* Keep track of their bleeding and any health changes during the study",[26,27],"Menorrhagia","Uterine Fibroids",[27,26],"RECRUITING","2026-04-27",{"date":32,"type":33},"2026-05-01","ACTUAL",{"date":35,"type":33},"2026-02-03",{"date":37,"type":20},"2028-09-03",{"name":39,"class":40},"JW Pharmaceutical","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100632522","phase-1-to-evaluate-the-safety-pharmacokinetic-and-pharmacodynamics-of-jw0061-in-healthy-volunteers-100632522","NCT07514780","To Evaluate the Safety, Pharmacokinetic and Pharmacodynamics of JW0061 in Healthy Volunteers","A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Clinical Trial to Evaluate the Safety, Pharmacokinetic and Pharmadynamics of JW0061 Following Topical Application in Korean and Caucasians Healthy Adults","Inclusion Criteria:\n\n* Body weight between 50.0 kg and 90.0 kg, and BMI between 18.5 and 29.9 kg\u002Fm².\n* Determined to be healthy and eligible by the investigator based on medical history, physical examination, and clinical laboratory tests.\n* Capable of providing written informed consent and willing to comply with all study requirements and restrictions.\n\nExclusion Criteria:\n\n* Presence of clinically significant scalp conditions that may interfere with safety assessments.\n* History of malignancy within 5 years prior to screening.\n* History of hypersensitivity or allergy to the study drug or its components.",true,"ALL","55 Years",{"count":53,"type":20},104,[55],"PHASE1","This clinical study is a phase 1, randomized, double-blind, placebo-controlled, dose escalation clinical trial to evaluate the safety, pharmacokinetic and pharmacodynamics of JW0061 following topical application in Korean and Caucasians healthy adults.",[58],"Healthy","2026-04-20",{"date":61,"type":33},"2026-04-23",{"date":63,"type":33},"2026-04-13",{"date":65,"type":20},"2027-04-30",{"name":39,"class":40},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":77,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":41},"100633229","efficacy-and-safety-of-pitavastatinezetimibe-in-dyslipidemia-patients-with-metabolic-syndrome-an-observational-study-100633229","NCT07523971","Efficacy and Safety of Pitavastatin\u002FEzetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study","A Multi-center, Open-label, Observational Study to Evaluate the Efficacy and Safety of Pitavastatin\u002FEzetimibe Tablets in Patients With Dyslipidemia Who Also Have Metabolic Syndrome","PIVOT","Inclusion Criteria:\n\n1. Age 19 years old at the time of written informed consent\n2. Subjects diagnosed with dyslipidemia and metabolic syndrome\n3. Subjects who had no treatment history with lipid regulators within 4 weeks prior to Visit1 or who had insufficient therapeutic effects from 8 weeks of treatment with lipid regulators using the same dosage and administration\n4. Subjects who meet the following LDL-C levels according to the classification of cardiovascular disease risk groups\\* at Visit 1 or who are planned to be treated with Pitavastatin\u002FEzetimibe Tablets based on the judgment of the investigator\n5. Subjects who voluntarily sign the informed consent form for study participation\n\nExclusion Criteria:\n\n1. Individuals for whom Pitavastatin\u002FEzetimibe Tablets is contraindicated as specified in the label's Precautions for Use\n2. Individuals who were treated with other investigational products (IP) or investigational devices within 4 weeks prior to participation in the present study or who are expected to have such treatment during the present study\n3. Individuals who are considered to have difficulty participating in the study for other reasons based on the judgment of the investigator",{"count":76,"type":20},10000,"1 Year","OBSERVATIONAL","The purpose of this study is to evaluate the efficacy and safety of Pitavastatin\u002FEzetimibe tablets (a fixed-dose combination of Pitavastatin and Ezetimibe) in patients with dyslipidemia who also have metabolic syndrome in a real-world clinical setting.\n\nAs this is an observational study, participants will be treated according to the investigator's medical judgment and routine clinical practice. The study aims to observe the changes in low-density lipoprotein cholesterol (LDL-C) levels from baseline to 24 weeks and 48 weeks of treatment. Safety will also be assessed by monitoring any adverse events occurring during the 48-week observation period.",[81],"Dyslipidemias",[83],"Metabolic Syndrome","2026-04-05",{"date":63,"type":33},{"date":87,"type":33},"2025-06-25",{"date":89,"type":20},"2027-06",{"name":39,"class":40},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":95,"conditions":102,"keywords":104,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":41},"100626928","phase-4-glycemic-variability-of-combination-therapies-in-t2dm-100626928","NCT07442006","Glycemic Variability of Combination Therapies in T2DM","A Multicenter Study to Evaluate Efficacy and Safety","Inclusion Criteria:\n\n* Inadequate glycemic control despite treatment with Metformin (≥ 1,000mg\u002Fday) and SGLT-2 inhibitor.\n\nExclusion Criteria:\n\n* History of acute or chronic metabolic acidosis\n* Moderate to severe renal impairment (eGFR \\\u003C 45 mL\u002Fmin\u002F1.73m²)\n* Severe hepatic impairment\n* History of heart failure (NYHA Class III\u002FIV)",{"count":99,"type":20},178,[101],"PHASE4",[103],"Type 2 Diabetes Mellitus (T2DM)",[105],"Glycemic Variability","2026-02-26",{"date":108,"type":33},"2026-03-02",{"date":110,"type":33},"2025-10-29",{"date":112,"type":20},"2027-03-31",{"name":39,"class":40},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":41},"100565511","phase-3-evaluate-the-efficacy-and-safety-of-co-administration-of-jw0104c2402-in-patients-with-hypertension-and-dyslipidemia-100565511","NCT06643130","Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia","A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia","Inclusion Criteria:\n\n* Patients with hypertension and dyslipidemia\n\nExclusion Criteria:\n\n* The subject not meet the specified msBP and LDL-C level",{"count":122,"type":20},162,[23],"A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients with Hypertension and Dyslipidemia",[126,127],"Hypertension","Dyslipidemia","2025-09-02",{"date":130,"type":33},"2025-09-09",{"date":132,"type":33},"2024-12-02",{"date":134,"type":20},"2026-04",{"name":39,"class":40},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":49,"sex":50,"minAge":17,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":146,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":41},"100570166","phase-1-to-evaluate-the-safetytolerability-and-pharmacokinetic-characteristics-in-healthy-volunteers-100570166","NCT06703710","To Evaluate the Safety\u002FTolerability and Pharmacokinetic Characteristics in Healthy Volunteers","A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Phase 1 Clinical Trial to Evaluate the Safety\u002FTolerability and PK Characteristics, and to Explore Food Effect and Ethnic Difference of JW2286 in Healthy Volunteers","Inclusion Criteria:\n\n* Healthy Korean or Caucasian volunteers\n\nExclusion Criteria:\n\n* Individuals with a clinically significant disease or history\n* Individuals with a history of a gastrointestinal disorder or surgery\n* In the case of all female individuals with childbearing potential, except for those who are surgically sterile","50 Years",{"count":145,"type":20},72,[55],"This clinical trial is a randomized, double-blind, placebo-controlled, single ascending dose, phase 1 clinical trial to evaluate the safety\u002Ftolerability and pharmacokinetic characteristics, and to explore food effect and ethnic difference of JW2286 after oral administration in healthy adults.",[58],"2025-01-09",{"date":151,"type":33},"2025-01-13",{"date":153,"type":33},"2025-01-06",{"date":155,"type":20},"2026-01",{"name":39,"class":40},""]